FOXD2-AS1 also exerts oncogenic actions on carcinogenesis including progression of bladder cancer (Su et al., 2018), glioma (Ni et al., 2019), cutaneous melanoma (Ren et al., 2019), colorectal cancer (Zhu et al., 2018), esophageal squamous cell carcinoma (Bao et al., 2018), and non–small cell lung cancer (Rong et al., 2017). Here, FOXD2 is linked to urinary bladder carcinoma.